Jiangsu Recbio Technology Co., Ltd. Class H (2179) AI Stock Analysis

• Market Cap: HK$3.74B
• Dividend Yield: N/A
• Average Volume (3M): 205.20K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.35
• Revenue Growth: N/A
• EPS Growth: 3.30%
• Country: HK
• Employees: 531
• Sector: Healthcare
• Sector Strength: 39
• Industry: Biotechnology
• EPS (TTM): -0.71
• Shares Outstanding: 316,138,700
• 10 Day Avg. Volume: 121,850
• 30 Day Avg. Volume: 205,200
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$8.00
• Price Target Upside: 2.56% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 42 Neutral
• Price Target: HK$7.50 ▼(-3.85%Downside)

The overall stock score reflects significant financial challenges, including persistent losses and negative cash flows, coupled with high leverage. Technical indicators provide a neutral outlook, while valuation metrics highlight unprofitability. These factors collectively result in a low overall score, suggesting caution for potential investors.

Jiangsu Recbio Technology Co., Ltd. Class H Business Overview & Revenue Model

Company Description

Jiangsu Recbio Technology Co., Ltd. Class H (2179) is a biotechnology company based in Jiangsu, China. The company specializes in the research, development, and commercialization of innovative vaccines. Recbio's core products focus on addressing infectious diseases and public health needs, leveraging advanced technologies to create next-generation vaccines that enhance immune responses and safety profiles.

How the Company Makes Money

Jiangsu Recbio Technology Co., Ltd. generates revenue primarily through the sale of its vaccine products. The company's revenue model is centered around developing proprietary vaccines and bringing them to market. This involves a combination of direct sales to healthcare providers and partnerships with pharmaceutical companies for distribution and commercialization. Additionally, Recbio may earn income from licensing agreements and collaborations with other biotechnology firms or research institutions, enabling them to expand their product reach and leverage shared research capabilities.

Jiangsu Recbio Technology Co., Ltd. Class H Financial Statement Overview

Summary

Jiangsu Recbio Technology Co., Ltd. faces significant financial challenges, with declining revenue, persistent losses, and negative cash flows. High leverage and negative equity in some periods add to the risk, despite slight balance sheet improvements.

Income Statement

The income statement reveals a challenging financial position. Revenue has decreased from 2023 to 2024, indicating a negative growth trend. Gross Profit Margin is positive, but Net Profit Margin is significantly negative due to substantial net losses, reflecting high operational costs and inefficiencies. The company is experiencing negative EBIT and EBITDA Margins, highlighting ongoing operational challenges and lack of profitability.

Balance Sheet

The balance sheet indicates moderate risk. The company has a negative equity position in some past years, which has improved slightly but remains vulnerable. High Debt-to-Equity ratios suggest significant leverage, posing financial risk. The Return on Equity (ROE) is negative, reflecting continued losses. However, the company maintains a reasonable level of assets relative to liabilities, providing some stability.

Cash Flow

Cash flow analysis shows a concerning trend. Operating cash flow is consistently negative, reflecting cash outflows from operations. Free Cash Flow is also negative, indicating that the company is not generating sufficient cash to cover capital expenditures. The lack of positive cash flow growth suggests ongoing financial strain and limited liquidity.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	27.00M	30.38M	5.33M	6.20M	1.46M
Gross Profit	15.95M	22.34M	5.33M	6.20M	1.46M
EBITDA	-523.97M	-569.87M	-847.67M	-590.00M	-134.91M
Net Income	-562.39M	-571.96M	-719.20M	-702.67M	-211.13M
Balance Sheet
Total Assets	1.94B	2.19B	2.31B	1.92B	1.05B
Cash, Cash Equivalents and Short-Term Investments	448.31M	837.76M	1.33B	1.18B	681.71M
Total Debt	889.10M	650.79M	282.63M	76.72M	26.13M
Total Liabilities	1.41B	1.12B	656.53M	245.92M	2.06B
Stockholders Equity	529.32M	1.07B	1.66B	1.67B	-1.01B
Cash Flow
Free Cash Flow	-636.66M	-862.18M	-888.04M	-710.79M	-241.07M
Operating Cash Flow	-464.82M	-638.07M	-579.54M	-472.92M	-70.34M
Investing Cash Flow	-279.04M	9.42M	-378.43M	68.70M	-258.59M
Financing Cash Flow	218.06M	275.27M	839.44M	1.23B	680.38M

Jiangsu Recbio Technology Co., Ltd. Class H Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 7.80
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2179, the sentiment is Negative. The current price of 7.8 is below the 20-day moving average (MA) of 8.00, below the 50-day MA of 8.19, and below the 200-day MA of 8.25, indicating a bearish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 41.60 is Neutral, neither overbought nor oversold. The STOCH value of 50.96 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2179.

Jiangsu Recbio Technology Co., Ltd. Class H Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1875	71 Outperform	HK$1.92B	47.97	4.92%	―	38.48%	―
Sector *	60 Neutral	HK$16.77B	6.05	-6.36%	3.69%	11.62%	-23.89%
2157	57 Neutral	HK$14.78B	―	-51.40%	―	58.75%	-1310.16%
3681	52 Neutral	HK$3.72B	―	-75.64%	―	42.21%	29.52%
2616	49 Neutral	HK$9.72B	―	-22.23%	―	-14.17%	76.00%
2179	42 Neutral	HK$3.74B	―	-69.97%	―	―	3.30%

Jiangsu Recbio Technology Co., Ltd. Class H Corporate Events

Jiangsu Recbio Receives CSRC Approval for Domestic Share Issuance

Jiangsu Recbio Technology Co., Ltd. has received approval from the China Securities Regulatory Commission (CSRC) for the issuance of domestic shares to a target subscriber. This approval is valid for 12 months and requires the company to adhere strictly to the submitted filing documents. The issuance is subject to certain conditions and uncertainties, and the company will provide further updates as necessary. Shareholders and potential investors are advised to exercise caution when dealing with the company’s securities.

Jiangsu Recbio Partners with Biological E for HPV Vaccine Expansion

Jiangsu Recbio Technology Co., Ltd. has entered into a product licensing agreement with India’s Biological E Company for its recombinant HPV 9-valent vaccine, REC603. This agreement allows Biological E to develop, manufacture, and commercialize the vaccine in India and markets led by UNICEF and PAHO, marking a significant step for Jiangsu Recbio in expanding its international market presence. The collaboration leverages Biological E’s extensive experience in vaccine R&D and commercialization, potentially enhancing the availability of the vaccine in high-demand regions, given India’s large population and the global need for effective HPV vaccines.

Jiangsu Recbio Technology Secures Shareholder Approval for Key Resolutions at AGM

Jiangsu Recbio Technology Co., Ltd. held its Annual General Meeting on June 20, 2025, where all proposed resolutions were passed. These resolutions included approvals of financial reports, work reports, and the appointment of a board observer, as well as amendments to the Articles of Association. The successful passage of these resolutions indicates strong shareholder support and positions the company for continued strategic development and operational enhancements.

Jiangsu Recbio Technology Announces 2024 AGM with Key Resolutions

Jiangsu Recbio Technology Co., Ltd. has announced its 2024 Annual General Meeting scheduled for June 20, 2025, where various resolutions will be considered, including financial reports, profit distribution plans, and changes in business scope. The meeting’s outcomes could significantly impact the company’s strategic direction and stakeholder interests, particularly with resolutions on share issuance and amendments to the Articles of Association.

Jiangsu Recbio to Boost Market Presence with H Share Full Circulation Plan

Jiangsu Recbio Technology Co., Ltd. has announced its participation in the H Share Full Circulation Plan, aiming to convert 141,953,490 unlisted shares into H shares. This strategic move is expected to significantly increase the company’s H share count to 94.85% of its total share capital, enhancing liquidity and potentially strengthening its market position on the Hong Kong Stock Exchange.

Jiangsu Recbio Announces Board Composition and Roles

Jiangsu Recbio Technology Co., Ltd. has announced the composition of its board of directors, highlighting the roles and functions of each member. This announcement provides clarity on the governance structure of the company, which is crucial for stakeholders to understand the leadership dynamics and decision-making processes.